Includes technologies from the women’s and reproductive health spaces including infertility, contraception, gynecological disorders as well as female-specific cancers like ovarian, uterine, and breast.
This technology involves a collection of patient-derived breast cancer models developed from freshly isolated tumor tissues obtained within 60 minutes post-surgery. This approach is differentiated by its rapid tissue procurement process and meticulous adherence to protocols that capture the intrinsic complexity of breast cancer. - Provides a robust preclinical model that offers enhanced phenotypic fidelity compared to conventional breast cancer cell lines.
Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. The loss of E-cadherin, a key component of adherens junctions, hyperactivates the IGF1R pathway, enhancing sensitivity to IGF1R-targeted therapy in breast cancer cells. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.